Shots:

• The filling is based on results of P-III SOLO-1 study assessing Lynparza (300mg bid) vs PBO as a monothx in 391 newly-diagnosed patients with BRCA-m advanced ovarian cancer in ratio (2:1) for up to two years
• The study showed improved results with reduction in the risk of disease progression or death by 70%- remained progression free @36 mos. (60% vs 27%). These results were presented at ESMO 2018
• Lynparza is a novel inhibitor of PARP- approved for advance and metastatic breast cancer in Japan. Lynparza has received a PDUFA date in Q1’19 for BRAC-m advance ovarian cancer & is jointly developed by AstraZeneca & MSD

Ref: AstraZeneca | Image: AstraZeneca